Cassava then released the altered data in a press release and investor deck, which led the SEC to allege that the company and ...

Read Deep Dive: Patients & Partnerships in full pharmaphorum’s digital magazine Deep Dive provides objective, issue-driven ...

CD40 agonists have had mixed results in cancer to date, with Roche discontinuing its selicrelumab candidate after ...

It is all over bar the shouting win for the US election, with Donald Trump set to claim the Presidency, potentially with the ...

GLP-1 agonist Wegovy (semaglutide) brought in DKK 17.3 billion ($2.49 billion) in the period, restoring earlier levels of ...

BEAM-101 is an ex vivo genetic therapy delivered as part of an autologous haematopoietic stem cell transplant (HSCT) after a conditioning chemotherapy regimen to destroy the bone marrow and allow it ...

AstraZeneca's shares have fallen more than 8% on speculation about an anti-corruption probe in China, its second-largest ...

Field medical education before launch is linked to greater launch success, improving treatment adoption by up to 50%. New ...

Focus ultrasound (FUS) has the potential to revolutionise therapy to the same degree that magnetic resonance imaging (MRI) scanning revolutionised diagnosis, says Kassell. The effect of the treatment ...

Journey Medical has claimed FDA approval for its Emrosi therapy for rosacea, which it thinks could become a "standard of care ...

With a mix of breakout sessions, hands-on workshops, and in-depth discussions, learning from real-world case studies that ...

CRUK has invested more than £43 million into the RadNet programme since it was launched in 2019, and Manchester is one of ...